HEARTGENETICS is at Web Summit this week.
HEARTGENETICS was chosen one of 66 startups to represent Portugal at Web Summit 2016.
Over the years, Web Summit has become “Europe’s largest and most important technology marketplace”. This year more than 53,056 tech CEOs, founders, startups, investors and political leaders driving change across the world are coming together in Lisbon for Web Summit. They’ll be looking for answers to the questions posed by the tech revolution we’re living through.
Get in touch with HEARTGENETICS to know about how we innovate in genetic testing and software tools useful for clinical diagnostics.
We are exhibiting at stand number A-659 in the HealthTech Exhibition Area of Pavilion 1 on Day 3 of the event, Thursday, November 10.
HEART GENETICS PRESS RELEASE.
HEARTGENETICS is a Portuguese biotech & data-driven company developing certified medical devices that make genetic testing actionable & cost-effective.
The innovative and easy to use clinical decision support and reporting system, HEARTDECODE®, allows genetic laboratories to perform comprehensive, simpler to read and more straight to the point genetic reports, supporting accurate diagnosis, prognosis and disease risk stratification.
HEARTDECODE® is already certified as a CE/IVD medical device.
Associated with the HEARTDECODE® system, the HEARTGENETICS team has developed a set of innovative CE-IVD genetic testing kits for cardiovascular diseases that can be prescribed in several areas, such as Obstetrics, Cardiology, Cardio-Oncology, Nutrigenetics and Pharmacogenetics.
HEARTGENETICS is a spin-off of the Instituto Superior Técnico in Lisbon, VC-backed since April 2013 by Venture Capital players, ES Ventures SCR S.A. and Beta Capital S.A. Presently is headquartered at the Biocant Park, Portugal ́s leading biotechnological centre, where several major biotechnology start-ups and a number of global players are located.
HEARTGENETICS labs are ISO NP 9001:2008 and ISO 13485:2012 certified for Quality Management System and apply an External Quality Assessment program from UK NEQAS.
HEARTGENETICS’ team is a highly qualified team of PhDs, engineers, entrepreneurs and MBAs to cover all aspects of its business from genetics, genomics and informatics to management, economics and marketing.
“Our ambition is to become a global genetic testing and data-driven company, delivering useful, accessible and SMART solutions for the genetic testing industry”
Ana Teresa Freitas, CEO
Knowledge Through Genetics
Ana Teresa Freitas, CEO
HeartGenetics, Genetics and Biotechnology SA
Biocant Park, Núcleo 4, Lote 4A, 3060-197 Cantanhede, Portugal
Contact@heartgenetics.com | www.heartgenetics.com | +351 231 410 896
This article was published on November 7, 2016.